Compare TTD & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTD | MDGL |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.0B | 12.0B |
| IPO Year | 2016 | 2005 |
| Metric | TTD | MDGL |
|---|---|---|
| Price | $22.46 | $531.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 34 | 12 |
| Target Price | $46.63 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 16.1M | 352.5K |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.38 | ★ 41.32 |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $2,896,284,000.00 | $180,133,000.00 |
| Revenue This Year | $14.01 | $58.39 |
| Revenue Next Year | $12.63 | $48.55 |
| P/E Ratio | $25.29 | ★ N/A |
| Revenue Growth | ★ 18.47 | N/A |
| 52 Week Low | $19.74 | $265.00 |
| 52 Week High | $91.45 | $615.00 |
| Indicator | TTD | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 61.75 |
| Support Level | $21.06 | $503.93 |
| Resistance Level | $28.59 | $610.00 |
| Average True Range (ATR) | 1.19 | 19.22 |
| MACD | 0.34 | -0.29 |
| Stochastic Oscillator | 71.88 | 56.33 |
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on devices like computers, smartphones, and connected TVs. It uses data in an iterative manner to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry, and it generates revenue from fees based on a percentage of what its clients spend on advertising.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.